Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a cat and dog image cbAugust 22 2017

A veterinary medicine containing fluralaner, used to treat cats and dogs for fleas and ticks, has been found to increase the risk of convulsion in the pet.

 The European Medicines Agency has issued a statement saying that the product Bravecto “continues to have an acceptable safety profile.” However, the package leaflet will now have to be updated within the next six months to “include convulsions as a new side effect that is reported very rarely, ie, less than one animal out of 10,000 animals treated.

“Veterinarians and pet owners will also be advised to use Bravecto with caution in dogs with epilepsy.”

Bravecto can be given as a chewable treatment to dogs or as a spot-on treatment for cats and dogs. It is also used as part of a treatment strategy for the control of flea allergy dermatitis. An estimated 18 million doses have been given in the EU, and 41.6 million doses worldwide.

“By 15 August 2017, suspected side effects had been reported electronically for 5,326 dogs, of which 2,144 were in the EU. Between February 2014 and 15 August 2017, deaths had been reported in 1,265 dogs worldwide and 342 in the EU,” said the EU. “Each report relates to dogs under different health conditions, often receiving multiple medicines, therefore these figures may or may not be related to the use of Bravecto in dogs.”

Pet owners with concerns of side effects experienced by their animal should contact the vet. Veterinarians and healthcare professionals are also advised to report any potential adverse reactions following the use of Bravecto to the National Office of Animal Health, NOAH.

EMA announcement     
NOAH – Bravecto data sheet        

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...